Piramal Pharma Solutions (PPS) made this third acquisition of FY21 as it entered into an agreement to purchase a 100% stake in Hemmo Pharmaceuticals Pvt. Ltd for ₹775 crore, the companies said in a joint statement on Wednesday. PPS is the contract development and manufacturing organization (CDMO) of Piramal Pharma Ltd (PPL).
— Mint
The acquisiton will see Piramal Pharma Solutions venture into the development and manufacturing of peptide APIs and expand its existing offerings.
Desai & Diwanji advised Hemmo Pharmaceuticals led by a team of partner Natasha Treasurywala, senior associate Shireen Langrana and associate Kunal Pradhan.
Economic Laws Practice (ELP) acted as the legal counsel for Piramal Pharma solutions in the deal, led by a team including partner Aakanksha Joshi associate partner Ananthram Ganesh senior associate Ashima Saxena.
2021-03-31
Deal value: Over INR 775 crores (USD 106 million)
This deal report is based on a firm's press release and may be only partially complete. Some firms or names of advisers may be therefore be missing.
Click here if you are working with a law firm that has not been credited for this deal, and we will update the report promptly.
Click to show comment
at your own risk
(alt+c)
By reading the comments you agree that they are the (often anonymous) personal views and opinions of readers, which may be biased and unreliable, and for which Legally India therefore has no liability. If you believe a comment is inappropriate, please click 'Report to LI' below the comment and we will review it as soon as practicable.
threads most popular
thread most upvoted
comment newest
first oldest
first
threads most popular
thread most upvoted
comment newest
first oldest
first